Drug
Ispinesib clinical trials
Also written SB-715992 and CK0238273.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2004 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 7 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 9
National Cancer Institute (NCI) (7) · GlaxoSmithKline (5) · NCIC Clinical Trials Group (2) · Cytokinetics (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ispinesib is read from its arms, and is right about nine times in ten.
Testing it · 15
- SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver CancerCompletedPhase 2NCIC Clinical Trials GroupNCT00095992Written as ispinesib
- A Study of Ispinesib in Metastatic Breast CancerTerminatedPhase 1CytokineticsNCT00607841Written as Ispinesib
- Study Of Ispinesib In Subjects With Breast CancerCompletedPhase 2GlaxoSmithKlineNCT00089973Written as Ispinesib
- SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedPhase 2National Cancer Institute (NCI)NCT00095628Written as ispinesib
- SB-715992 in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedPhase 2National Cancer Institute (NCI)NCT00103311Written as ispinesib
- Ispinesib in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT00354250Written as ispinesib
- SB-715992 in Treating Patients With Metastatic or Recurrent Malignant MelanomaCompletedPhase 2NCIC Clinical Trials GroupNCT00095953Written as ispinesib
- SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or PaclitaxelCompletedPhase 2National Cancer Institute (NCI)NCT00096499Written as ispinesib
- Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedPhase 1National Cancer Institute (NCI)NCT00363272Written as ispinesib
- SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedPhase 1National Cancer Institute (NCI)NCT00101244Written as ispinesib
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedPhase 1National Cancer Institute (NCI)NCT00098826Written as ispinesib
- Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung CancerCompletedPhase 2GlaxoSmithKlineNCT00085813Written as Ispinesib
- Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian CancerCompletedPhase 2GlaxoSmithKlineNCT00097409Written as Ispinesib
- SB-715992 In Combination With Docetaxel In Patients With Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT00169520Written as SB-715992
- Ispinesib In Combination With Capecitabine In Patients With Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT00119171Written as Ispinesib
Given in every arm · 1 — ispinesib is usual care beside what is tested
Codes
What other systems call ispinesib · ClinicalTrials.gg INT004881
- MeSH (NLM) C508757ispinesibOne source NLM
- UNII (FDA) BKT5F9C2NIISPINESIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27166496ispinesibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38131IspinesibOne source FDA
- DrugBank DB06188One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C508757 | ispinesib | One source NLM |
| UNII (FDA) | BKT5F9C2NI | ISPINESIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27166496 | ispinesib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38131 | Ispinesib | One source FDA |
| DrugBank | DB06188 | — | One source Wikidata |
Also registered as ispinesib mesylate (UNII R6ZMD4UH3D).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.